Drug-induced effects on erlotinib metabolism

New England Journal of Medicine

Volumn 365, Issue 4, 2011, Pages 379-380

  Mir, Olivier ^a   Blanchet, Benoit ^a   Goldwasser, François ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; CYTOCHROME P450 3A5; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ESCITALOPRAM; FENOFIBRATE; MULTIDRUG RESISTANCE PROTEIN 1;

AGED; CANCER STAGING; CASE REPORT; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG METABOLISM; DRUG WITHDRAWAL; EXON; FEMALE; GENE DELETION; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; LETTER; LIQUID CHROMATOGRAPHY; LUNG ADENOCARCINOMA; PARONYCHIA; PLEURA EFFUSION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; THORAX PAIN;

EID: 79960856289     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1105083     Document Type: Letter

References (5)

1. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-79. (Pubitemid 32591445)
2. Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002;30:1280-7. (Pubitemid 35265837)
3. Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 2011;364:947-55.
4. Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM. Use of fibrates in the United States and Canada. JAMA 2011;305:1217-24.
5. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674-80. (Pubitemid 46625492)